Follow
Tumor development
Tumor development, or tumorigenesis, broadly describes the process by which normal cells gain malignant properties. Tumor development includes growth functions like cellular differentiation, proliferation, and metastasis.
-
OCT 17, 2013 | 12:00 PMC.E. CREDITS
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...Speaker: Kenneth Buetow, PhD, FACMIOCT 17, 2013 | 11:00 AMC.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...Speaker: George Poste, DVM, DSc, PhDOCT 17, 2013 | 10:00 AMC.E. CREDITS
Prostate cancer epithelial cells depend on androgens for their survival. Because of this dependence, androgen deprivation therapy is the major treatment of advanced prostate cancer. Such ther...Speaker: Donald Tindall, PhDOCT 17, 2013 | 9:00 AMC.E. CREDITS
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...Speaker: Lori M. Millner, PhDOCT 17, 2013 | 7:00 AM
Whenever there is cell death, apoptotic cell free DNA fragments appear in the circulation of the host. These fragments, typically 145-160 base pairs in size, represent a minute fraction of to...Speaker: Charles Cantor, PhDOCT 16, 2013 | 3:00 PMC.E. CREDITS
Deregulation of ACK1, a non-receptor tyrosine kinase originally identified by its ability to bind to GTP-bound Cdc42 (hence the name: activated Cdc42-associated kinase)(Manser et al., 1993),...Speaker: Henry Chang, PhDOCT 16, 2013 | 2:00 PMC.E. CREDITS
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...Speaker: Roberto Chiarle, MDOCT 16, 2013 | 1:00 PMC.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...Speaker: Elahe A Mostaghel, MD, PhDOCT 16, 2013 | 1:00 PMC.E. CREDITS
The remarkable diversity we see between different cell types in the human body is governed by the specificity attained through transcriptional and epigenetic regulatory programs. Cancer is a...Speaker: Jessica C. Mar, PhDOCT 16, 2013 | 11:00 AMC.E. CREDITS
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...Speaker: Ross L. Cagan, PhDOCT 16, 2013 | 11:00 AM
"SuperSelective" primers, by virtue of their unique design, enable only a few molecules of a mutant sequence to generate amplicons in conventional, real-time PCR assays without interference...Speaker: Fred Kramer, PhDOCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...Speaker: Michael J Mann, MDOCT 16, 2013 | 9:00 AMC.E. CREDITS
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...Speaker: Charles M. Perou, PhDOCT 16, 2013 | 7:00 AMC.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...Speaker: Andrew Armstrong, MD ScM FACPOCT 16, 2013 | 7:00 AMC.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...Speaker: R. Claudio Aguilar, PhD
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
Speaker:
Nicola Normanno, MD
AUG 22, 2013 | 5:00 PM
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
AUG 22, 2013 | 1:00 PM
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
Speaker:
Kenneth Buetow, PhD, FACMI
Presented at: Genetics and Genomics Virtual Event Series 2013
AUG 21, 2013 | 4:00 PM
C.E. CREDITS
High throughput transcriptomic analyses have shown that most of the human genome is dynamically transcribed to produce an extraordinary range of overlapping and interlacing intronic, intergen...
Speaker:
John Mattick, PhD,AO, FAA, FRCPA
Presented at: Genetics and Genomics Virtual Event Series 2013
AUG 21, 2013 | 12:00 PM
Whenever there is cell death, apoptotic cell free DNA fragments appear in the circulation of the host. These fragments, typically 145-160 base pairs in size, represent a minute fraction of to...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
OCT 26, 2011 | 2:00 PM
Autophagy is a normal degradative pathway that involves the sequestration of entire organelles, protein complexes, and misfolded proteins in a membrane vacuole called the autophagosome. The ...
OCT 17, 2013 | 12:00 PM
C.E. CREDITS
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
Speaker:
Kenneth Buetow, PhD, FACMI
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
Speaker:
George Poste, DVM, DSc, PhD
OCT 17, 2013 | 10:00 AM
C.E. CREDITS
Prostate cancer epithelial cells depend on androgens for their survival. Because of this dependence, androgen deprivation therapy is the major treatment of advanced prostate cancer. Such ther...
Speaker:
Donald Tindall, PhD
OCT 17, 2013 | 9:00 AM
C.E. CREDITS
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...
Speaker:
Lori M. Millner, PhD
OCT 17, 2013 | 7:00 AM
Whenever there is cell death, apoptotic cell free DNA fragments appear in the circulation of the host. These fragments, typically 145-160 base pairs in size, represent a minute fraction of to...
Speaker:
Charles Cantor, PhD
OCT 16, 2013 | 3:00 PM
C.E. CREDITS
Deregulation of ACK1, a non-receptor tyrosine kinase originally identified by its ability to bind to GTP-bound Cdc42 (hence the name: activated Cdc42-associated kinase)(Manser et al., 1993),...
Speaker:
Henry Chang, PhD
OCT 16, 2013 | 2:00 PM
C.E. CREDITS
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
Speaker:
Roberto Chiarle, MD
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...
Speaker:
Elahe A Mostaghel, MD, PhD
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
The remarkable diversity we see between different cell types in the human body is governed by the specificity attained through transcriptional and epigenetic regulatory programs. Cancer is a...
Speaker:
Jessica C. Mar, PhD
OCT 16, 2013 | 11:00 AM
C.E. CREDITS
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...
Speaker:
Ross L. Cagan, PhD
OCT 16, 2013 | 11:00 AM
"SuperSelective" primers, by virtue of their unique design, enable only a few molecules of a mutant sequence to generate amplicons in conventional, real-time PCR assays without interference...
Speaker:
Fred Kramer, PhD
OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
Speaker:
Michael J Mann, MD
OCT 16, 2013 | 9:00 AM
C.E. CREDITS
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...
Speaker:
Charles M. Perou, PhD
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Speaker:
Andrew Armstrong, MD ScM FACP
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...
Speaker:
R. Claudio Aguilar, PhD
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
Speaker:
Nicola Normanno, MD
AUG 22, 2013 | 5:00 PM
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
AUG 22, 2013 | 1:00 PM
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
Speaker:
Kenneth Buetow, PhD, FACMI
Presented at: Genetics and Genomics Virtual Event Series 2013
AUG 21, 2013 | 4:00 PM
C.E. CREDITS
High throughput transcriptomic analyses have shown that most of the human genome is dynamically transcribed to produce an extraordinary range of overlapping and interlacing intronic, intergen...
Speaker:
John Mattick, PhD,AO, FAA, FRCPA
Presented at: Genetics and Genomics Virtual Event Series 2013
AUG 21, 2013 | 12:00 PM
Whenever there is cell death, apoptotic cell free DNA fragments appear in the circulation of the host. These fragments, typically 145-160 base pairs in size, represent a minute fraction of to...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
OCT 26, 2011 | 2:00 PM
Autophagy is a normal degradative pathway that involves the sequestration of entire organelles, protein complexes, and misfolded proteins in a membrane vacuole called the autophagosome. The ...